OPTIC: Ponatinib in chronic-phase CML
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2021-12-13
Просмотров: 402
Описание: Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, discusses results from a post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) in the ongoing Phase II OPTIC trial (NCT02467270). Patients received either 45mg, 30mg, or 15mg of ponatinib, and clinical benefit was shown across all three cohorts. Patients with T315I mutations in BCR-ABL1 reported better outcomes when receiving 45mg and patients without detectable mutations had more favorable outcomes with lower doses. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
